Aims: TAF, a novel tenofovir prodrug, has demonstrated noninferior efficacy to TDF with superior bone and renal safety in virally suppressed CHB patients with eGFR (by Cockcroft-Gault; eGFR<sub>CG</sub>) ³50 mL/min when switched from TDF....
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A107095388
( Jeong Heo ) ; ( Harry L.A. Janssen ) ; ( Young-suk Lim ) ; ( Edward J. Gane ) ; ( Claire Fournier ) ; ( Sang Hoon Ahn ) ; ( Owen Tsang ) ; ( Wan-long Chuang ) ; ( Aric Josun Hui ) ; ( Magdy Elkhashab ) ; ( Chi-yi Chen ) ; ( Wei-wen Su ) ; ( John F. Flaherty ) ; ( Anuj Gaggar ) ; ( Susanna Tan ) ; ( Audrey H. Lau ) ; ( Vithika Suri ) ; ( Shuyuan Mo ) ; ( Mani Subramanian ) ; ( Syed-mohammed Jafri ) ; ( Kosh Agarwal ) ; ( Pietro Lampertico ) ; ( Giulo Marchesini ) ; ( Carla S. Coffin ) ; ( Yi-hsiang Huang )
2020
-
500
학술저널
127-128(2쪽)
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
Aims: TAF, a novel tenofovir prodrug, has demonstrated noninferior efficacy to TDF with superior bone and renal safety in virally suppressed CHB patients with eGFR (by Cockcroft-Gault; eGFR<sub>CG</sub>) ³50 mL/min when switched from TDF....
Aims: TAF, a novel tenofovir prodrug, has demonstrated noninferior efficacy to TDF with superior bone and renal safety in virally suppressed CHB patients with eGFR (by Cockcroft-Gault; eGFR<sub>CG</sub>) ³50 mL/min when switched from TDF. The efficacy and safety of virally suppressed patients on TDF with renal impairment who were switched to TAF were evaluated in this Phase 2 study.
Methods: CHB patients with renal impairment taking TDF for ³48 weeks and virally suppressed for ³6 months with HBV DNA <20 IU/mL at screening were enrolled into 2 cohorts: 1) moderate-severe renal impairment (eGFR<sub>CG</sub> 15 to <60mL/min) and 2) ESRD (eGFR<sub>CG</sub> <15 mL/min) patients on chronic HD. All patients were switched to TAF 25 mg QD for 96 weeks. Co-primary endpoints were proportion with HBV DNA <20 IU/mL and graded adverse events (AEs)/lab abnormalities at Week 24.
Results: 93 patients (Mod-severe impairment 78; ESRD 15) were enrolled from 26 sites in 8 countries. Median age was 65 years, 74% male, 77% Asian, 83% HBeAg-negative, up to 60% had low BMD at hip and/or spine, and 60% and 24% had a history of HTN and/or diabetes, respectively. Key efficacy/safety results at Week 24 are summarized in the Table. All patients on treatment at Week 24 maintained HBV DNA <20 IU/mL and a high proportion had normal ALT levels. Relative to baseline levels, switching to TAF from TDF resulted in increases in hip/spine BMD, decreases in bone turnover markers, as well as increases in eGFR<sub>CG</sub> and decreases in renal tubular markers. TAF was well tolerated with few having Grade 3 or 4 AEs (8%) and no discontinuations due to AEs.
Conclusions: In renally-impaired CHB patients, including ESRD patients on HD, viral suppression was well maintained and the bone and renal safety were improved 24 weeks after switching from TDF to TAF.
Tacotsubo Cardiomyopathy Secondary to Pyogenic Liver Abscess
Helicobacter Pylori Prevalence in Chronic Liver Disease Patients by Using 14CUrea Breath Test